• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Hamilton Alex P. sold $39,834 worth of shares (125,000 units at $0.32), decreasing direct ownership by 71% to 50,000 units (SEC Form 4)

    6/27/24 6:25:36 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MGRX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hamilton Alex P.

    (Last) (First) (Middle)
    C/O MANGOCEUTICALS, INC.
    15110 N. DALLAS PARKWAY, SUITE 600

    (Street)
    DALLAS TX 75248

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    MANGOCEUTICALS, INC. [ MGRX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/25/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 06/25/2024 S 16,574 D $0.31(1) 158,426 D
    Common Stock 06/26/2024 S 108,426 D $0.32(2) 50,000 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This transaction was executed in multiple trades at prices ranging from $0.32 to $0.31, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
    2. This transaction was executed in multiple trades at prices ranging from $0.33 to $0.32, inclusive. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
    /s/ Alex P. Hamilton 06/27/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MGRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MGRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

      DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based pouch innovation company specializing in stimulant and functional pouches. This acquisition marks a strategic expansion into the

      4/25/25 9:00:00 AM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • Mangoceuticals Expands into $33 Billion Addressable Diabetes Market Through its Exclusive Rights to Market and Sell Patented and Clinically Proven Diabetinol® in the USA and Canada

      Diabetinol® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace DALLAS, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has entered into a Master Distribution Agreement (the "Agreement") to secure the exclusive licensing and distribution rights for Diabetinol® within the United States and Canada. Diabetinol® is a plant-based nutraceutical clinically supporte

      3/25/25 9:00:00 AM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • Mangoceuticals Announces the Launch of "PeachesRx" - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments

      Dallas, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products via a secure telemedicine platform under the brand MangoRx, proudly announces the official launch of PeachesRx, an innovative women's health and wellness brand focused on providing cutting-edge, convenient treatments tailored to women's unique health needs. These new and innovative women's health and wellness products will be made available via a secure telemedicine platform located at www.PeachesRx.com. PeachesRx will debut with a strong focus on compounded GLP-1 receptor agoni

      2/20/25 7:00:00 AM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care

    $MGRX
    Financials

    Live finance-specific insights

    See more
    • Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

      Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness. The acquired patent encompasses nutraceutical compositions derived from functional mushrooms, including well-known varieties such as Cordyceps sinensi

      12/19/24 5:33:00 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

      Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues. During the six months ending June 30, 2024, MangoRx's shareholder equity increased to $13,829,445, compared to $774,754 as of December 31, 2023, reflecting an increase of 1,685%, or $13,054,691. A substantial

      8/15/24 9:25:00 AM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care

    $MGRX
    Leadership Updates

    Live Leadership Updates

    See more

    $MGRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MGRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

      DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based pouch innovation company specializing in stimulant and functional pouches. This acquisition marks a strategic expansion into the

      4/25/25 9:00:00 AM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Mangoceuticals Inc.

      SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)

      8/27/24 7:45:22 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Mangoceuticals Inc. (Amendment)

      SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)

      6/5/24 5:15:19 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • New insider Isaac Antonios claimed no ownership of stock in the company (SEC Form 3)

      3 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

      1/21/25 4:30:13 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • Chief Financial Officer Johnston Eugene M was granted 25,000 shares, increasing direct ownership by 187% to 38,334 units (SEC Form 4)

      4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

      11/12/24 5:06:32 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • Chief Executive Officer Cohen Jacob D. gifted 800,000 shares and received a gift of 800,000 shares (SEC Form 4)

      4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

      8/27/24 7:41:46 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care

    $MGRX
    SEC Filings

    See more
    • Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

      8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)

      5/23/25 5:27:00 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Mangoceuticals Inc.

      10-Q - MANGOCEUTICALS, INC. (0001938046) (Filer)

      5/15/25 4:58:17 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care
    • Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)

      5/6/25 5:01:36 PM ET
      $MGRX
      Misc Health and Biotechnology Services
      Health Care